Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Lymphomas
NCT03119467 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21
Last updated 2019-12-27
Summary
A Phase I/Ib, Study to Evaluate Safety and Efficacy of RP4010, in Patients with Relapsed or Refractory Lymphomas
Conditions
Interventions
- DRUG
-
RP4010
Escalating doses starting at 25 mg
Sponsors & Collaborators
-
Rhizen Pharmaceuticals SA
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-05-11
- Primary Completion
- 2019-11-29
- Completion
- 2019-12-19
- FDA Drug
- Yes
Countries
- United States
- Australia
Study Locations
More Related Trials
-
Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
NCT05563844 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
NCT05190068 ·Status: COMPLETED ·Phase: PHASE1
-
Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT05979857 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.
NCT05293912 ·Status: TERMINATED ·Phase: PHASE1
-
p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies
NCT02846935 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients
NCT03141203 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma
NCT05966233 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma
NCT05716087 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell Lymphoma
NCT04231370 ·Status: UNKNOWN ·Phase: PHASE2
-
Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma
NCT05427812 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
NCT00052442 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma
NCT04362007 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT05784987 ·Status: UNKNOWN ·Phase: NA
-
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas
NCT03220347 ·Status: TERMINATED ·Phase: PHASE1
-
A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma
NCT05274997 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT04442022 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma
NCT00655668 ·Status: TERMINATED ·Phase: PHASE2
-
A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia
NCT00587457 ·Status: TERMINATED ·Phase: PHASE1
-
PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma
NCT03120000 ·Status: WITHDRAWN ·Phase: PHASE2
-
Imexon for Relapsed Follicular and Aggressive Lymphomas
NCT01314014 ·Status: COMPLETED ·Phase: PHASE2
-
Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
NCT02436707 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of CN1 in Combination With CN401 in Adult Patients With Relapsed/Refractory Lymphoid Malignancies
NCT04880564 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Treatment of Relapsed or Refractory Natural Killer/T Cell Lymphoma
NCT03107962 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
NCT03369964 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
NCT05121103 ·Status: TERMINATED ·Phase: PHASE1